ArticleCost effectiveness and resource allocation : C/E2026
Use of resources and cost in the management of gastrointestinal hemorrhage caused by oral anticoagulants: a retrospective cohort analysis.
Article in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOral anticoagulants (OACs) used to treat nonvalvular atrial fibrillation (NVAF) are frequently associated with complications, especially gastrointestinal hemorrhage (GH). The aim was to determine the use of resources and costs in the in-hospital treatment of GH in a group of patients with NVAF from Colombia.
methodsThis was a retrospective study of a cohort of patients who were diagnosed with NVAF and treated with an OAC (apixaban, rivaroxaban, dabigatran or warfarin) between 2018 and 2022 and who were hospitalized for GH. Information on diagnoses, GH location, administered medications, procedures, hospital stay, and health care costs was collected, adjusted to 2022.
resultsIn total, 59 patients from nine different cities were identified, the mean age was 82.9 ± 12.6 years, and most were men (61.0%) who were admitted to nine clinics for GH. Upper GH was the most frequently identified form (78.0%). The most commonly used OACs were apixaban (44.1%), rivaroxaban (35.6%), warfarin (15.3%) and dabigatran (5.1%). The mean hospital stay was 6.4 ± 5.9 days, and 18.3% of the patients were admitted to the intensive care unit. Patients also received medications that increase the risk of bleeding, such as acetylsalicylic acid (45.8%), the antiplatelet inhibitor P2Y12 (15.3%) and systemic glucocorticoids (23.7%). The average direct cost of all hospital care was USD 872 ± 1315 per patient, which corresponds to 13% of the country’s gross domestic product per capita.
conclusionsGH patients with NVAF generates a significant cost for the use of resources such as medications, procedures and care that affect the country’s health system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.